Clinical Trials
9 trialsNCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05839470 2023-11-15
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05751265 2023-06-22
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05640726 2022-12-07
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Fujian Cancer Hospital
Phase 2 Unknown
NCT05551767 2022-09-23
Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer
City Clinical Oncology Hospital No 1
Phase 2 Unknown
NCT04149015 2019-11-04
Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03045770 2017-02-07
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
Fujian Cancer Hospital
Phase NA Unknown
NCT00577057 2013-08-22
Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
Hospital Authority, Hong Kong
Phase NA Unknown
NCT00563927 2010-07-07
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
Hospital Authority, Hong Kong
Phase NA Unknown